Adding a GLP-1 receptor agonist or tirzepatide for adults with type 2 diabetes who are living with obesity, should be considered if: they have been taking initial therapy for at least 3 months and further medicines are needed to reach their individualised glycaemic targets and they are not already taking a GLP-1 receptor agonist or tirzepatide For adults with type 2 diabetes who are living with obesity who need further medicines to reach their individualised glycaemic targets and for whom a GLP-1 receptor agonist or tirzepatide is contraindicated, not tolerated, not appropriate or not effective: offer to add a DPP-4 inhibitor to their current treatment if this is contraindicated, not tolerated or not effective, offer to add: a sulfonylurea or pioglitazone or an insulin-based treatment (see the section on insulin-based treatments) For adults with type 2 diabetes who are living with obesity who need further medicines to reach their individualised glycaemic targets and are already taking a GLP-1 receptor agonist or tirzepatide, offer to add: a sulfonylurea or pioglitazone or an insulin-based treatment (see the section on insulin-based treatments) (6) Adults with chronic kidney disease If type 2 diabetes and an estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73 m2: offer modified-release metformin and an SGLT-2 inhibitor
This treatment reduces food cravings, aids blood sugar control, and enhances feelings of fullness
Examples include polysaccharides, polyphenols, and alkaloids
The study protocol was approved by the Institutional Ethics Committee for Biomedical and Healthcare Research
This approach enhances patient safety and adherence to prescribed therapies, reducing the likelihood of complications
What should you ask a prescriber before starting compounded semaglutide
